| Autor: |
Schefler, Amy C, Skalet, Alison, Oliver, Scott C N, Mason, John, Daniels, Anthony B, Alsina, Katherina M, Plasseraud, Kristen M, Monzon, Federico A, Firestone, Brian |
| Zdroj: |
Melanoma Management; February 2020, Vol. 7 Issue: 1 p17-25, 9p |
| Abstrakt: |
Aim:The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods:Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results:A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion:Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
